SOUTH SAN FRANCISCO, CA--(Marketwire - December 10, 2007) - Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that a poster summarizing interim data from a Phase I/II clinical trial evaluating SB-743921 in patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease was presented at the 2007 Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. SB-743921 is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division, being developed by Cytokinetics under a collaboration and license agreement with GlaxoSmithKline.
